Application of a capsaicin rinse in the treatment of burning mouth syndrome

Objective: To examine the efficacy of a new topical capsaicin presentation as an oral rinse in improving the symptoms of burning mouth syndrome (BMS).Study design: A prospective, double-blind, cross-over study was made of 30 patients with BMS. There were 7dropouts; the final study series thus comprised 23 individuals. The patients were randomized to two groups: (A)capsaicin rinse (0.02%) or (B) placebo rinse, administered during one week. After a one-week washout period, the patients were then assigned to the opposite group. Burning discomfort was scored using a visual analog scale(VAS): in the morning before starting the treatment, in the afternoon on the first day of treatment, and at the end of the week of treatment in the morning and in the afternoon. The same scoring sequence was again applied one week later with the opposite rinse. Results: The mean patient age was 72.65 ± 12.10 years, and the duration of BMS was 5.43 ± 3.23 years on average. Significant differences in VAS score were recorded in the capsaicin group between baseline in the morning (AM1)or afternoon (AA1) and the end of the week of treatment (AA7)(p=0.003 and p=0.002, respectively).Conclusion: The topical application of capsaicin may be useful in treating the discomfort of BMS, but has some limitations (AU)

Application of a capsaicin rinse in the treatment of burning mouth syndrome.

OBJECTIVE: To examine the efficacy of a new topical capsaicin presentation as an oral rinse in improving the symptoms of burning mouth syndrome (BMS). STUDY DESIGN: A prospective, double-blind, cross-over study was made of 30 patients with BMS. There were 7 dropouts; the final study series thus comprised 23 individuals. The patients were randomized to two groups: (A) capsaicin rinse (0.02%) or (B) placebo rinse, administered during one week. After a one-week washout period, the patients were then assigned to the opposite group. Burning discomfort was scored using a visual analog scale (VAS): in the morning before starting the treatment, in the afternoon on the first day of treatment, and at the end of the week of treatment in the morning and in the afternoon. The same scoring sequence was again applied one week later with the opposite rinse. RESULTS: The mean patient age was 72.65 ± 12.10 years, and the duration of BMS was 5.43 ± 3.23 years on average. Significant differences in VAS score were recorded in the capsaicin group between baseline in the morning (AM1) or afternoon (AA1) and the end of the week of treatment (AA7)(p=0.003 and p=0.002, respectively). CONCLUSION: The topical application of capsaicin may be useful in treating the discomfort of BMS, but has some limitations.

Burning mouth syndrome: correlation of treatment to clinical variables of the disease.

OBJECTIVE: Burning mouth syndrome (BMS) is a complex disorder with a still uncertain etiopathogenesis. A number of treatments have been used in application to BMS, though without clearly successful results. The present study compares the improvement in BMS obtained as a result of different treatment modalities in relation to the clinical characteristics of the patients. STUDY DESIGN: A retrospective cohort study was made of 115 patients with BMS (109 females and 6 males) subjected to different treatments with a view to improving the symptoms. The clinical variables examined included the duration of the disorder, the location of the burning sensation, its daily variations and relationship with meals. The parameters were measured using a visual analog scale (VAS) applied at baseline and again after two weeks of treatment. RESULTS: The mean patient age was 70 ± 11.41 years, and the mean duration of the syndrome was 7.16 ± 2.63 years. The tongue was the most frequently affected location. Anxiolytic treatment afforded the best results (p < 0.001), and the patients with the shortest duration of disease showed the best improvement with treatment (p = 0.005). CONCLUSION: The greatest treatment efficacy corresponded to anxiolytic drugs, and treatment was more effective when introduced early after the diagnosis of BMS.

Manejo clínico-odontológico del paciente con cardiopatía isquémica: actualización / Dental management of the patient with ischemic heart disease: an update

La cardiopatía isquémica es la primera causa de mortalidad en los países desarrollados. Los protocolos tradicionales a seguir para realizar el tratamiento dental en estos pacientes con angina de pecho o infarto de miocardio se basaban en la clasificación de riesgo ASA (American Society of Anesthesiologists) y en la espera mínima de un período de 6 meses postinfarto para poder realizar un manejo más seguro. Los avances en las técnicas diagnósticas y en los tratamientos médicos y quirúrgicos en estos enfermos han permitido desarrollar patrones de valoración del riesgo más precisos y poder realizar los tratamientos odontológicos y de cirugía bucal en un período de tiempo menor desde que se sufrió el infarto con márgenes de seguridad aceptables (AU)